Elanco's Negasunt and Tanidil Receive FDA Emergency Authorization for New World Screwworm Treatment in Livestock

Key Takeaways

• FDA, EPA, and USDA granted emergency authorization for Elanco’s Negasunt Powder and Tanidil against New World screwworm in livestock
• Authorization provides veterinarians and livestock producers with prevention and treatment options before the parasite is detected in the U.S.
• Emergency action demonstrates federal agencies’ commitment to rapid response against emerging animal health threats

---

Federal Agencies Grant Emergency Authorization for Livestock Protection

Elanco Animal Health has received emergency authorization from federal agencies for two veterinary products to combat New World screwworm in livestock. The U.S. Food and Drug Administration (FDA), Environmental Protection Agency (EPA), and Department of Agriculture (USDA) approved Negasunt™ Powder (coumaphos, propoxur, sulfanilamide topical powder) and Tanidil™ (coumaphos, propoxur) for emergency use.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Proactive Measures Against Parasitic Threat

The emergency authorization provides veterinarians and livestock producers with critical prevention and treatment options before New World screwworm is detected in the United States. This parasitic fly poses significant threats to livestock health and agricultural economics, making preparedness essential for the industry.

New World screwworm larvae feed on living tissue of warm-blooded animals, causing severe wounds and potentially fatal infections if left untreated. The parasite was previously eradicated from the U.S. but remains a concern due to potential reintroduction from affected regions.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Industry Response

The authorization reinforces Elanco’s position as a leader in livestock health innovations and demonstrates the company’s ability to respond rapidly to emerging veterinary needs. Both products contain active ingredients proven effective against screwworm infestations, with Negasunt Powder offering additional antimicrobial properties through sulfanilamide.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Regulatory Coordination Highlights Preparedness

The coordinated response from multiple federal agencies underscores the U.S. government’s commitment to protecting agricultural interests and animal welfare. This multi-agency approach ensures comprehensive regulatory coverage for both drug approval and environmental safety considerations.

Veterinarians can now access these treatments through appropriate channels, ensuring rapid deployment if screwworm cases emerge. The authorization represents a critical component of the nation’s animal health security infrastructure.

---

Frequently Asked Questions

What is New World screwworm and why is it dangerous to livestock?

New World screwworm is a parasitic fly whose larvae feed on living tissue of warm-blooded animals, causing severe wounds and potentially fatal infections. It poses significant economic and health threats to livestock operations.

When will these treatments be available to veterinarians?

The emergency authorization is now in effect, allowing veterinarians to access Negasunt Powder and Tanidil through appropriate regulatory channels for use against screwworm infestations.

How do these Elanco products work against screwworm?

Both products contain coumaphos and propoxur as active ingredients that are effective against screwworm larvae. Negasunt Powder also includes sulfanilamide, which provides additional antimicrobial properties to prevent secondary infections.

Related coverage

• EU secures emergency Favipiravir deliveries for hantavirus response
• World Lightproof Bottle Opaque Liners Market: Pharma Growth to 2035
• Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates